Sarepta Therapeutics | SRPT - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Capricor Therapeutics 3.05M 2.46M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Gilead Sciences USD 240M 15M 2026-03
Incyte USD 569K 13K 2026-03
Insmed USD 20.08M 517K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Moderna USD 11.49B 36B 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novavax USD 5.82M 342K 2025-12
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12